IDH2 and astrocytoma (excluding glioblastoma): The patient was histologically diagnosed with WHO Grade 4 astrocytoma, IDH-mutant (IDH1 R132H mutation, MGMT promoter methylation, 1p19q codeletion, TERT C250T mutation, TERT C228T wildtype, IDH2 wildtype, and BRAF wildtype), and experienced two recurrences after surgery and concurrent chemoradiotherapy, with intolerance to TMZ during the treatment process.